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Frequency and Severity of Neutropenia Associated with Food and
Drug Administration Approved and Compounded Formulations of
Lomustine in Dogs with Cancer
J.H. Burton, S.D. Stanley, H.K. Knych, C.O. Rodriguez, K.A. Skorupski, and R.B. Rebhun
Background: Compounded lomustine is used commonly in veterinary patients. However, the potential variability in these
formulations is unknown and concern exists that compounded formulations of drugs may differ in potency from Food and
Drug Administration (FDA)-approved products.
Hypothesis/Objectives: The initial objective of this study was to evaluate the frequency and severity of neutropenia in
dogs treated with compounded or FDA-approved formulations of lomustine. Subsequent analyses aimed to determine the
potency of lomustine obtained from several compounding pharmacies.
Animals: Thirty-seven dogs treated with FDA-approved or compounded lomustine.
Methods: Dogs that received compounded or FDA-approved lomustine and had pretreatment and nadir CBCs performed
were eligible for inclusion. Variables assessed included lomustine dose, neutrophil counts, and severity of neutropenia.
Lomustine 5 mg capsules from 5 compounding sources were tested for potency using high-pressure liquid chromatography
(HPLC) with ultraviolet (UV) detection.
Results: Twenty-one dogs received FDA-approved lomustine and 16 dogs were treated with lomustine prescribed from a
single compounding pharmacy. All dogs treated with FDA-approved lomustine were neutropenic after treatment; 15 dogs
(71%) developed grade 3 or higher neutropenia. Four dogs (25%) given compounded lomustine became neutropenic, with 2
dogs (12.5%) developing grade 3 neutropenia. The potency of lomustine from 5 compounding pharmacies ranged from 50 to
115% of the labeled concentration, with 1 sample within 10% of the labeled concentration.
Conclusions and Clinical Importance: These data support broader investigation into the potency and consistency of
compounded chemotherapy drugs and highlight the potential need for greater oversight of these products.
Key words: Canine; CCNU; Chemotherapy.
Compounding is the customized preparation ofdrugs that are not commercially available in the
desired formulation or strength.1 Compounding of vet-
erinary drugs is widely performed and is occasionally a
necessity because of the lack of available Food and
Drug Administration (FDA)-approved drugs for ani-
mals. In veterinary oncology, compounded drugs may
be used to more safely dose small dogs and cats with
products that have a narrow therapeutic index. Com-
pounding also may be needed when shortages of com-
mercially available drugs occur. A number of
compounding pharmacies exist to meet the needs of vet-
erinarians, but there is concern as to whether com-
pounded agents are as efficacious and of similar quality
compared to FDA-approved products. Studies evaluat-
ing compounded omeprazole in horses, and com-
pounded itraconazole, ciclosporin, and trilostane in
dogs have indicated that compounded drugs are not
always equivalent in potency with respect to the active
pharmaceutical ingredient, and subsequent efficacy fail-
ures are more frequent as compared to the FDA-
approved product.2–5
Lomustine, a chemotherapy agent with demonstrated
efficacy against several malignancies in dogs, was
unavailable for commercial purchase as of May 2013
because of the discontinuation of sale of the FDA-
approved formulation.6 As a result, lomustine was rou-
tinely prescribed through a compounding pharmacy by
veterinary oncologists at our institution for patients
requiring the drug as part of their anticancer treatment.
As with many chemotherapeutics, lomustine has a nar-
row therapeutic index. Neutropenia frequently occurs
after treatment with this drug and 2 previous studies
evaluating the efficacy of lomustine against relapsed
lymphoma and mast cell tumors in dogs identified that
neutropenia was the dose-limiting toxicity, with median
neutrophil counts of approximately 1,400/lL 1 week
after treatment.7,8 During the 10 months that
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compounded formulations of lomustine were being pre-
scribed by clinicians at the University of California,
Davis Veterinary Medical Teaching Hospital, clinical
observation suggested that dogs experienced fewer neu-
tropenic events compared to previous clinical experience
with FDA-approved formulation of lomustine. To fur-
ther investigate this clinical suspicion, the initial objec-
tive of this study was to evaluate the frequency and
severity of neutropenia in dogs treated with an FDA-
approved formulation of lomustine as compared to
dogs treated with lomustine obtained from a single vet-
erinary compounding pharmacy. A subsequent objective
was to assess the initial potency of lomustine capsules
obtained from 5 veterinary compounding pharmacies.
Materials and Methods
Case Selection and Record Review
Medical records from the University of California, Davis
Veterinary Medical Teaching Hospital were reviewed from January
1, 2012 to February 28, 2014 for dogs given their first dose of
lomustine, either a compounded or the FDA-approved formula-
tion. Inclusion criteria included a known date of lomustine admin-
istration and CBC performed before dosing as well as a nadir
CBC performed 6–10 days after the first dose.
Data regarding the following variables were abstracted from each
dog’s medical record: signalment, body weight, body surface area
(BSA), cancer diagnosis, whether they had previously received other
chemotherapy or were treatment na€ıve, lomustine dosage, date and
dose of first lomustine administration. Both the intended and actual
dosages of lomustine were recorded because these dosages generally
vary for FDA-approved lomustine because capsules are only avail-
able in 10 mg and 40 mg strengths. Data collected regarding hema-
tologic variables included dates of pretreatment and nadir CBC,
number of days after lomustine administration the CBC was per-
formed, and baseline and nadir neutrophil counts. The severity of
neutropenia after lomustine treatment was determined using the
Veterinary Cooperative Oncology Group – Common Terminology
for Adverse Events (VCOG-CTCAE) v1.1.9
Lomustine Potency Analysis
Analytical reference standard for lomustinea was obtained. Five
veterinary compounding pharmacies were selected based on their
advertisements in national veterinary publications and their ability
to compound lomustine. Purchased compounded formulations of
lomustine with labeled concentrations of 5.0 mg were analyzed for
potency. Individual capsules were weighed and then opened to
remove the lomustine, which was emptied onto a wax paper sheet,
weighed, and transferred to an amber vial, which was wrapped
with aluminum foil to further protect from light exposure. The
empty capsule was then reweighed.
A reference standard solution of lomustine was prepared in 100%
methanol at a concentration of 1.0 mg/mL; the standard reference
material was purchased from certified vendorsa and certificates of
analysis that reported the quality and purity data were provided.
Before analysis, calculations were made so the concentration of
lomustine in each capsule could be determined when compared to
the reference standard. For each capsule, an amount containing the
calculated 5 mg was diluted with 5 mL of methanol: H2O (10:90 v/
v) to make each test solution. Each 50 lL test sample aliquot was
transferred containing the methanol: H2O (10:90 v/v) to solubilize
lomustine for analysis. The process was repeated for duplicate sam-
pling of each preparation. The duplicate aliquots of each prepara-
tion were analyzed using high-pressure liquid chromatography
(HPLC) with ultraviolet (UV) detectionb with a C18 reverse-phase
column (2.1 9 100 mm, 3 l).c The mobile phase was composed of
50:50 acetonitrile: H2O with 0.1% formic acid with an isocratic tech-
nique used throughout the analysis at a flow rate of 0.5 mL/min.
The column temperature was maintained at 30°C by column oven.
The UV detector was set to collect the following wavelengths: 254,
230, 215, and 274 nm. The injection volume was 40 lL.
Statistical Analysis
Continuous data were described using median and range and
categorical data as frequencies and percentages. Differences among
groups were assessed using the Mann–Whitney test for continuous
data. For categorical data, Fisher’s exact test was used for vari-
ables with 2 categories and the Chi-squared test for variables with
>2 categories. A P value of <.05 was considered statistically signifi-
cant. All statistical analyses were performed using commercially
available software.d
Results
Fifty-five dogs that received lomustine during the
study time period were identified on electronic medical
database search. Eighteen of these cases did not have a
baseline or nadir CBC for review, resulting in 37 cases
that met the criteria for inclusion into this study.
Twenty-one dogs were treated with the FDA-approved
formulation of lomustine from June 11, 2011 to May 8,
2013 and 16 dogs received a compounded formulation
of lomustine from May 13, 2013 to February 21, 2014.
The compounded lomustine was dispensed from a single
veterinary compounding pharmacy for all dogs in this
portion of the study. Information regarding patient sig-
nalment, tumor type and previous treatment are
reported in Table 1. The median body weight and body
surface area (BSA) for the group of dogs that received
compounded lomustine were significantly less than
those of dogs that received FDA-approved formulations
of lomustine (Table 1; P = .02 for both variables).
Table 2 summarizes the planned and actual dosages of
lomustine as well as baseline and nadir neutrophil
counts. There was no statistical difference between the
planned and actual lomustine dosages between the dogs
that received FDA-approved or compounded formula-
tions of lomustine. The baseline median neutrophil count
before treatment was not significantly different between
dogs that received FDA-approved formulations of
lomustine (8,309/lL; range, 3,802–19,580/lL) and those
treated with compounded lomustine (7,879/lL; range,
4,440–38,059/lL; P = .81). Nadir neutrophil counts were
performed on day 6 (n = 1), day 7 (n = 21), day 8
(n = 11), day 9 (n = 2), and day 10 (n = 2) after CCNU
administration; median nadir neutrophil counts were not
statistically significant different between day 7, 8, 9, and
10 (P = .66). Neutropenia occurred in all 21 dogs
(100%) treated with FDA-approved lomustine and the
median neutrophil count 1 week post-treatment was 638/
lL (range, 42–2,941/lL). Significantly fewer dogs (n = 4;
25%) treated with compounded lomustine developed
neutropenia 1 week post-treatment with a median neu-
trophil count of 3,520/lL (range, 560–20,697/lL;
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P < .0001). Three dogs (19%) treated with compounded
lomustine had either no change (n = 1) or an increase
(n = 2) in neutrophil count from baseline to nadir. The
grade (severity) of neutropenia was assessed using the
VCOG-CTCAE v1.19 for each dog and is presented in
Table 3. Dogs were grouped according to the severity of
the neutropenia (no neutropenia and grade 1–2 versus
grade 3–5) and dogs treated with the FDA-approved for-
mulation of lomustine were significantly more likely to
develop ≥ grade 3 neutropenia (n = 15, 71%) as com-
pared to dogs treated with compounded lomustine
(n = 2, 12.5%; P < .001).
Compounded Lomustine Potency
Three 5.0 mg capsules of lomustine were obtained
from the veterinary compounding pharmacy that was
used to prescribe compounded lomustine to all dogs
that received compounded formulations of the drug in
this study. The capsules were analyzed within 10 days
of receipt from the compounding pharmacy. The 3 cap-
sules varied 7% among the weights of the lightest and
the heaviest (231.4, 244.8, and 249.3 mg). When ana-
lyzed for potency using HPLC-UV, the capsules were
determined to contain 50, 54, and 54% of the labeled
concentration of 5.0 mg.
Three capsules of lomustine 5.0 mg were obtained
from 4 additional veterinary compounding pharmacies
as well as the pharmacy from which the initial samples
were analyzed. When analyzed for potency, the samples
were determined to contain between 67 and 115% of
the labeled concentration of lomustine (Fig. 1). Only 1
veterinary compounding pharmacy provided samples
that fell within 10% of the labeled concentration,
which is the maximal variability in potency allowed for
FDA-approved pharmaceutical products.
Discussion
This study confirmed our clinical impression that the
frequency and severity of neutropenia associated with
lomustine administration was significantly decreased
when compounded formulations of lomustine were used
to treat cancer-bearing dogs. Additionally, significant
variability in the potency of compounded lomustine
from several sources was identified, with only 1 of the
veterinary compounding pharmacies providing potency
within 10% of the label-claimed concentration.
Myelosuppression, in particular neutropenia, is a
common sequela after lomustine administration and is
considered to be the dose-limiting toxicity for this drug.
Two previous publications evaluating use of lomustine
as treatment for dogs with mast cell tumors and
relapsed lymphoma reported median nadir neutrophil
counts of 1,452 cells/lL8 and 1,400 cells/lL7, respec-
tively. In these studies, occurrence of ≥ grade 3 neu-
tropenia was reported to be 41%8 and 42%7, and both
of these studies used a higher dosage of lomustine
(90 mg/m2) than given to dogs in this study and evalu-
Table 1. Patient demographics, tumor type, and
whether previous chemotherapy had been administered
for dogs treated with either FDA-approved or
compounded lomustine.
















Golden retriever 2 (9.5%) 2 (12.5%)
English bulldog 1 (4.8%) 2 (12.5%)
Mixed breed 3 (14.3%) 4 (25%)
Rottweiler 2 (9.5%) 0
Other (1 each)b 6 (28.6%) 4 (25%)
Age (years) 8.5 (3.6–12.2) 8.0 (0.7–12.0) .44
Sex
MC 10 (47.6%) 6 (37.5%) 1.0
M 1 (4.8%) 3 (18.8%)
FS 9 (42.9%) 6 (37.5%)
F 1 (4.8%) 1 (6.3%)
Weight (kg) 35.8 (8.7–63.6) 27.2 (3.9–43.8) .02
BSAc (m2) 1.08 (0.42–1.59) 0.9 (0.24–1.24) .02
Tumor Type
Lymphomad 5 (23.8%) 7 (43.8%) .44
Mast cell tumor 9 (42.9%) 5 (31.3%)
Histocytic
sarcoma
7 (33.3%) 4 (25%)
Previous
chemotherapy
Yes 13 (61.9%) 10 (62.5%) 1.0
No 8 (38.1%) 6 (37.5%)
aNA, not assessed.
bOther breeds included Beagle, Chihuahua, Standard Poodle,
Vizsla, Bassett hound, Boxer, Bull mastiff, Pit bull, Rhodesian
ridgeback, Miniature Schnauzer.
cBSA, body surface area.
dIncluded relapsed/refractory or cutaneous lymphoma.
Table 2. Lomustine dosages (planned and actual) and baseline and nadir neutrophil counts for dogs that received
either FDA-approved or compounded lomustine.
Variable
FDA-Approved Lomustine,
n = 21 Median (range)
Compounded Lomustine
n = 16 Median (range) P value
Planned lomustine dosage (mg/m2) 71 (65–80) 73.5 (45.8–80) .36
Actual lomustine dosage (mg/m2) 71.4 (61–77.8) 73.5 (45.8–80.6) .21
Baseline neutrophil count (103 cells/lL) 8.3 (3.8–19.6) 7.9 (4.4–38.1) .81
Post-tx CBC (days) 7 (6–10) 7 (7–10) .90
Nadir neutrophil count (103 cells/lL) 0.64 (0.04–2.9) 3.5 (0.56–20.7) <.0001
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ated a CBC 7 days after lomustine treatment. Although
the VCOG-CTCAE grading scheme had not been pub-
lished at the time of publication of these earlier studies,
both previous studies used the same criteria to define
grade 2, 3, and 4 neutropenias as the current VCOG-
CTCAE v1.1. This finding is further supported by a
study in which 58–84% of dogs treated with lomustine
90 mg/m2 with or without dexamethasone developed ≥
grade 3 neutropenia, with median neutrophils counts
ranging from 282 to 573 cells/lL at the nadir.10 In
another study, 57% of dogs that received lomustine
developed neutropenia, with 21% being ≥ grade 3, but
the median dosage of lomustine used in that study was
57.9 mg/m2 and ranged from 28.6 to 88.9 mg/m2, which
may explain the decreased frequency of neutropenia in
that study.11 We observed a higher frequency of ≥grade
3 neutropenia in dogs treated with the FDA-approved
lomustine in our study (71%). Evaluation of the nadir
CBC over a range of days (6–10 days) may have led to
a higher number of dogs diagnosed with neutropenia.
Because the majority of dogs had a CBC performed
7 days after treatment, however, we feel that this expla-
nation is less likely. The timing of absolute nadirs in
individual patients, however, is variable. Therefore, a
single CBC nadir is unlikely to represent an individual
dog’s absolute nadir even when performed at the same
time point as in other dogs. Nevertheless, allowing eval-
uation of a CBC between 6–10 days after treatment
may, in part, explain reported differences in frequency
and severity of neutropenia among historical studies
and between historical studies and our findings.
Our study employed occurrence of a well-documented
toxicity of a chemotherapy drug as a reflection of sys-
temic exposure to lomustine and potential surrogate of
antitumor activity of the drug. This approach was novel
in that lomustine has a narrow therapeutic window
accompanied by an established and accepted toxicity
profile that can be easily monitored clinically. Our data
raise concerns regarding the possibility of decreased effi-
cacy of compounded lomustine formulations, but this
outcome was not directly examined in our study. Ide-
ally, to evaluate exposure and efficacy of the com-
pounded versus FDA-approved formulation of the
drug, pharmacokinetic evaluation and tumor response
assessment would be primary outcome measures, but
this approach was not feasible in our study because a
variety of tumor types and stages of disease were
included. Prospective studies evaluating compounded
and FDA-approved formulations of chemotherapy
drugs could be performed to further investigate activity,
but ethical concerns must be taken into consideration in
light of our findings to ensure that cancer-bearing dogs
do not receive substandard treatment.
Our study was limited by issues inherent to most retro-
spective studies, including small sample sizes, lack of ran-
domization into treatment groups, and collection of data
from incomplete medical records. The median body
weight and BSA of the dogs that received compounded
lomustine were statistically lower than those of dogs that
were treated with FDA-approved formulations, but the
median dose of lomustine was not significantly different
between the groups. Some concern exists that a higher
number of dogs in the group that received compounded
lomustine would be at increased risk for developing
hematologic toxicities when using BSA to calculate
dosage because of smaller patient size.12 A standard
alternative dosing scheme, however, is not routinely
Fig 1. Bar graph of the percent potency of lomustine capsules
with a labeled concentration of 5 mg obtained from 5 veterinary
compounding pharmacies. The solid line indicates 100% of labeled
concentration and the dashed line represents 90% of labeled con-
centration, which is the minimum potency allowed for FDA-
approved products. The actual concentration of the samples
obtained from the 5 compounding pharmacies ranged from 67 to
115% of the labeled concentration, with only 1 compounding
pharmacy providing product that fell within 10% of the labeled
concentration.
Table 3. Severity of neutropenia as determined by VCOG-CTCAE for dogs that received either commercially avail-
able lomustine or a compounded formulation of lomustine.
Severity of neutropenia Neutrophil Count (cell/lL)
FDA-Approved
Lomustine (n = 21)
Compounded
Lomustine (n = 16)
None WNLa 0 12 (75%)
Grade 1 (mild) 1,500 – LLNb 2 (9.5%) 1 (6.3%)
Grade 2 (moderate) 1,000–1,499 4 (19%) 1 (6.3%)
Grade 3 (severe) 500–999 5 (24%) 2 (12.5%)
Grade 4 (life-threatening) <500 9 (43%) 0
Grade 5 (death) – 1 (4.8%) 0
aWNL, within normal limits.
bLLN, lower limit of normal.
Neutropenia and Compounded Chemotherapy 245
employed for small dogs receiving lomustine. Differences
in weight between the 2 groups might have been expected
to result in a higher number of dogs that received com-
pounded lomustine to develop neutropenia, but the
opposite was observed in this study because dogs devel-
oped more frequent and severe neutropenia after treat-
ment with FDA-approved lomustine.
We elected not to identify the compounding pharma-
cies from which lomustine was obtained for analysis in
this study because it would be irresponsible to condemn
or commend individual pharmacies based on a single
sample tested at a single time point. In fact, our intention
was not to identify ideal or substandard compounding
pharmacies because there are many possible explanations
for the observed variability. Furthermore, the potential
benefits afforded by accurately compounded formula-
tions in veterinary oncology are numerous and may
include more precise dosing for smaller patients as well
as optimization of low-dose chemotherapy protocols.
Publication of these findings solely was intended to high-
light potential inconsistencies that can occur with com-
pounded formulations of chemotherapy drugs. Although
we acknowledge that some compounding pharmacies
indeed provide certificates of analysis (either standardly
or upon request), we are unable to comment on the accu-
racy of these certificates as compared with our results
without disclosing information regarding individual
pharmacies. Nevertheless, the wide variability in the
potency of lomustine at the present time is concerning.
Although it is beyond the scope of our study to deter-
mine the source of variability among compounding phar-
macies, our results should alert prescribing veterinarians
to the potential hazards of prescribing compounded for-
mulations of chemotherapy drugs.
In conclusion, our results support broader investiga-
tion into the potency and consistency of compounded
chemotherapy drugs, particularly for agents expected to
be well tolerated with a less predictable adverse event
profile. These data also highlight the potential need for
more oversight of these compounded products to ensure
appropriate anticancer treatment for veterinary patients.
Footnotes
a Sigma-Aldrich, St. Louis, MO
b Agilent 1100 Binary LC, Santa Clara, CA
c Advanced Chromatography Technologies, Ltd, Aderdeen, UK
d Prism GraphPad, version 6.0, La Jolla, CA
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